GlassScriptPhysician profile
Jessica Awerman
NPI 1114455102
$11,462.29
in general payments reported to CMS, 2019-2025
28 companies · $2,705 in 2025
The $2,705 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $1,181 · 2023: $3,829 · 2024: $3,627 · 2025: $2,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,625 · Education: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,625.25 |
| Education | $535.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,789.64 | 2022-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $1,593.34 | 2022-2025 | |
| Janssen Biotech, INC. | $1,147.04 | 2022-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $950.63 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $814.33 | 2022-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $794.06 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $663.81 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $567.79 | 2022-2025 | |
| Amgen INC. | $495.59 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $421.89 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $318.35 | 2022-2025 | Nemluvio, Aklief |
| Pfizer INC. | $313.95 | 2022-2025 | |
| Dermavant Sciences, INC. | $296.94 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $290.70 | 2023-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $186.92 | 2023-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.55 | 2022-2024 | Spevigo |
| Janssen Scientific Affairs, LLC | $119.90 | 2021 | |
| Organon LLC | $99.96 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Fresenius Kabi USA, LLC | $94.91 | 2023-2024 | Idacio |
| Leo Pharma INC. | $68.23 | 2022-2024 | Adbry |
| Ani Pharmaceuticals, INC. | $41.63 | 2023 | Purified Cortrophin Gel |
| Celgene Corporation | $32.72 | 2024 | Sotyktu |
| Biofrontera INC. | $21.34 | 2025 | |
| Mylan Institutional INC. | $20.47 | 2023 | Fulphila |
| Botanix Sb INC | $20.10 | 2025 | Sofdra |
| Kyowa Kirin, INC. | $18.59 | 2023 | Poteligeo |
| Verrica Pharmaceuticals INC. | $15.91 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Awerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.